A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors
ConditionAdvanced Cancers
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorChia Tai Tianqing Pharmaceutical Group Co., Ltd.
About this trial
TQB3107 is a protein inhibitor that induces apoptosis and inhibits the proliferation of various tumor cells. This clinical study aims to evaluate the safety and tolerability of TQB3107 tablets in subjects with advanced malignancies, to determine the dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) (if any), and the recommended dose for Phase II (RP2D).
Eligibility criteria
Qualifiers
18 years ≤ age≤ 75 years (calculated from the date of signing the informed consent); Score 0~1 point, estimated survival ≥ 3 months；
Malignant tumors with no standard treatment regimen or disease progression or intolerance after prior standard therapy；
The major organs are functioning well；
Negative serum pregnancy test within 7 days prior to the first dose and must be a non-lactating subject, female and male subjects of childbearing potential should agree to use contraception throughout the study and for 6 months after the study ends;
Disqualifiers
Hematologic malignancy has or is suspected to involve the central nervous system, or primary central nervous system lymphoma;
Received any anti-cancer therapy such as major surgery, chemotherapy and/or radiotherapy, immunotherapy, or targeted therapy within 4 weeks prior to the first dose;
Combined with severe or not well-controlled diseases, which the investigator judges to be at greater risk of entering this study；
Those with a history of drug addiction or substance abuse；
Trial design
Treatments tested in this trial
- TQB3107 Tablets
Treatment groups
140 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov